U.S. regulators have stamped an approval on GlaxoSmithKline's combination meningitis vaccine, which is supposed to provide wide coverage against the life-threatening disease for young infants. The FDA's approval of the product, called Menhibrix, could give the London-based drugmaker an edge in the market for meningitis vaccines.
Pharma giant Pfizer is making progress in the Phase II trial of a vaccine for meningitis serogroup B, for which there are no such preventive treatments available. This week the New York-based drugmaker's trial got some ink from media near some of the study sites in the Midwest.
While vaccines against Streptococcus pneumoniae have cut the number of deaths from this bug that can cause pneumonia and meningitis, the number of cases has tripled in the past 50 years.
A team from Australia has shown positive immune responses in a Phase II trial of Pfizer's meningitis B vaccine in teenagers.
The European Medicines Agency has recommended approval for GlaxoSmithKline's ($GSK) conjugate vaccine against meningococcal disease in adults and children from the age of 12 months. The active...
A vaccine against meningococcal B disease, a devastating bacterial infection that is hard to diagnose and can kill in 24 hours, has come a step closer with infant Phase IIb data for Novartis' ($NVS)
The remaining type of meningitis for which no vaccine exists has finally met its match. In a study backed by Novartis ($NVS), researchers found the Swiss drug giant's experimental vaccine, dubbed...
Serum Institute of India's vaccine for meningitis beat out pricier alternatives from other vaccine makers, including GlaxoSmithKline. That's according to a study published in the New England Journal
Novartis appears to have made more progress in the battle against meningitis B. The Swiss drug giant says that its experimental vaccine Bexsero (a.k.a. 4CMenB) could protect against about 80 percent
The GAVI Alliance has committed $100 million to support a meningitis A vaccine called MenAfriVac developed by Seattle-based PATH. The vaccine, which was developed with the help of a $70 million